👤 Serina Huang

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
1370
Articles
1004
Name variants
Also published as: Ai-Chun Huang, Ai-long Huang, Aijie Huang, Ailong Huang, Aimin Huang, Alden Y Huang, An-Fang Huang, Annie Huang, Aohuan Huang, Ariane Huang, Baihai Huang, Baisong Huang, Bao-Hua Huang, Bao-Yi Huang, Baoqin Huang, Baoying Huang, Benjamin J Huang, Benlin Huang, Bevan E Huang, Bi Huang, Biao Huang, Bin Huang, Binfang Huang, Bing Huang, Bingcang Huang, Bingkun Huang, Bizhi Huang, Bo Huang, Bo-Shih Huang, Bor-Ren Huang, Bowen Huang, Boyue Huang, C Y Huang, Caihong Huang, Caiyun Huang, Can Huang, Canhua Huang, Caoxin Huang, Cathelin Huang, Catherine Huang, Chang Ming Huang, Chang X Huang, Chang-Jen Huang, Changjiang Huang, Chao Huang, Chao Wei Huang, Chao-Wei Huang, Chao-Yuan Huang, Chaolin Huang, Chaoqun Huang, Chaowang Huang, Chaoyang Huang, Chen Huang, Chen-Na Huang, Chen-Ping Huang, Cheng Huang, Chengcheng Huang, Chengrui Huang, Chenshen Huang, Chenxiao Huang, Chi-Cheng Huang, Chi-Shuan Huang, Chia-Chang Huang, Chia-Wei Huang, Chieh-Cheng Huang, Chieh-Liang Huang, Chien-Hsun Huang, Chih-Chun Huang, Chih-Hsiang Huang, Chih-Jen Huang, Chih-Ting Huang, Chih-Yang Huang, Chin-Chang Huang, Chin-Chou Huang, Ching-Shan Huang, Ching-Shin Huang, Ching-Tang Huang, Ching-Wei Huang, Chiu-Ju Huang, Chiu-Jung Huang, Chiun-Sheng Huang, Chong Huang, Chongbiao Huang, Christine S Huang, Chuan Huang, Chuanbing Huang, Chuanhong Huang, Chuanjiang Huang, Chuanjun Huang, Chuansheng Huang, Chuiguo Huang, Chun Huang, Chun-Mei Huang, Chun-Yao Huang, Chun-Yin Huang, Chunfan Huang, Chung-Hsiung Huang, Chunhong Huang, Chunjian Huang, Chunkai Huang, Chunlan Huang, Chunling Huang, Chunshuai Huang, Chunxia Huang, Chunyao Huang, Chunyi Huang, Chunying Huang, Chunyu Huang, Chuxin Huang, Chuying Huang, Congcong Huang, Cuiyu Huang, Da Huang, Dajun Huang, Dan Huang, Dane Huang, Danqing Huang, Dantong Huang, David Huang, David J Huang, De Huang, De-Jun Huang, Dejia Huang, Dengjun Huang, Dianhua Huang, Dishu Huang, Dong Huang, Donglan Huang, Dongmei Huang, Dongni Huang, Dongqin Huang, Dongqing Huang, Dongsheng Huang, Dongyu Huang, Du-Juan Huang, Emily C Huang, Enhao Huang, Enping Huang, Eric Huang, Erya Huang, F Huang, Fan Huang, Fang Huang, Fang-Ling Huang, Fangling Huang, Fei Huang, Fei Wan Huang, Feiruo Huang, Feiteng Huang, Feizhou Huang, Feng Huang, Fengxian Huang, Fengyu Huang, Franklin W Huang, Fu-Chen Huang, Fu-Mei Huang, Fubiao Huang, Fude Huang, Fuhao Huang, Furong Huang, G Huang, Gairong Huang, Gang Huang, Gao-Zhong Huang, Gaoxingyu Huang, Ge Huang, Guang-Jian Huang, Guang-Yun Huang, Guangjian Huang, Guangming Huang, Guangqian Huang, Guangrui Huang, Guanhong Huang, Guanling Huang, Guanning Huang, Guanqun Huang, Guanrong Huang, Guicheng Huang, Guodong Huang, Guohong Huang, Guoping Huang, Guoqian Huang, Guowei Huang, Guoxing Huang, Guoying Huang, Guoyong Huang, Guoyuan Huang, H Huang, H S Huang, Hai Huang, Haigang Huang, Haihong Huang, Hailin Huang, Haimiao Huang, Haixin Huang, Haiyan Huang, Han-Chang Huang, Hanxia Huang, Hao Huang, Hao-Fei Huang, Haobo Huang, Haochu Huang, Haomin Huang, Haoyu Huang, Haoyue Huang, Haozhang Huang, Haozhong Huang, He Huang, Hefeng Huang, Heguang Huang, Helen Huang, Heming Huang, Hengbin Huang, Heqing Huang, Hete Huang, Hong Huang, Hongbiao Huang, Hongcan Huang, Hongda Huang, Hongfei Huang, Hongfeng Huang, Honghui Huang, Hongou Huang, Hongqiang Huang, Hongyan Huang, Hongyang Huang, Hongyi Huang, Hongying Huang, Hongyu Huang, Hongyun Huang, Hsi-Yuan Huang, Hsien-Da Huang, Hsing-Yen Huang, Hsu Chih Huang, Hsuan-Cheng Huang, Hsuan-Ying Huang, Hu Huang, Hua Huang, Huafei Huang, Huaju Huang, Huan Huang, Huanhuan Huang, Huanliang Huang, Huapin Huang, Huashan Huang, Huayun Huang, Hui Huang, Hui-Huang Huang, Hui-Kuang Huang, Hui-Yu Huang, Huibin Huang, Huifen Huang, Huiling Huang, Huimin Huang, Huina Huang, Huiqiao Huang, Huixian Huang, Huixin Huang, Huiyan Huang, Huiyu Huang, Huizhe Huang, Huizhen Huang, Hy Huang, I-Chieh Huang, J V Huang, Janice J Huang, Jasmin Huang, Jeffrey K Huang, Jia Huang, Jia-Jia Huang, Jiaan Huang, Jiahui Huang, Jiajin Huang, Jiajun Huang, Jian Huang, Jian-Dong Huang, Jiana Huang, Jianbiao Huang, Jianbing Huang, Jianfang Huang, Jianfeng Huang, Jiangfeng Huang, Jiangtao Huang, Jiangwei Huang, Jianhua Huang, Jianlu Huang, Jianmin Huang, Jianming Huang, Jiansheng Huang, Jianzhen Huang, Jiao-Qian Huang, Jiaoti Huang, Jiaotian Huang, Jiaqi Huang, Jiawen Huang, Jiaxing Huang, Jiayu Huang, Jiayue Huang, Jie Huang, Jie Qi Huang, Jiechun Huang, Jieli Huang, Jieling Huang, Jieping Huang, Jin Huang, Jin-Di Huang, Jin-Feng Huang, Jin-Hong Huang, Jin-Yan Huang, Jinbao Huang, Jinfang Huang, Jing Huang, Jing-Fei Huang, Jingang Huang, Jinghan Huang, Jingjing Huang, Jingkun Huang, Jinglong Huang, Jingtao Huang, Jingxian Huang, Jingyong Huang, Jingyuan Huang, Jingyue Huang, Jinhua Huang, Jinling Huang, Jinlu Huang, Jinshu Huang, Jinxing Huang, Jinyan Huang, Jinzhou Huang, Jiuhong Huang, Jiyu Huang, Ju Huang, Juan Huang, Jucun Huang, Jun Huang, Jun-Hua Huang, Jun-You Huang, Junhao Huang, Junhua Huang, Junjie Huang, Junming Huang, Junning Huang, Junqi Huang, Junwen Huang, Junyuan Huang, Junyun Huang, Juxiang Huang, K Huang, K N Huang, Kai Huang, Kaipeng Huang, Kang Huang, Kangbo Huang, Kate Huang, Katherine Huang, Ke Huang, Ke-Ke Huang, Ke-Pu Huang, Kevin Huang, Kevin Y Huang, Kuan-Chun Huang, Kui-Yuan Huang, Kuiyuan Huang, Kun Huang, Kuo-Hsiang Huang, Kuo-Hung Huang, L Huang, L-B Huang, Laiqiang Huang, Lan Huang, Lanlan Huang, Lei Huang, Leijuan Huang, Li Huang, Li-Hao Huang, Li-Jiang Huang, Li-Juan Huang, Li-Jun Huang, Li-Ping Huang, Li-Rung Huang, Li-Wei Huang, Li-Yun Huang, Lian Huang, Liang Huang, Liang-Yu Huang, Liangchong Huang, Lianggui Huang, Libin Huang, Lige Huang, Lihua Huang, Lijia Huang, Lijiang Huang, Lijuan Huang, Lijun Huang, Lili Huang, Limin Huang, Liming Huang, Lin Huang, Linchen Huang, Ling Huang, Ling-Chun Huang, Ling-Jin Huang, Lingling Huang, Lining Huang, Linjing Huang, Linsheng Huang, Linxue Huang, Linyuan Huang, Liping Huang, Liqiong Huang, Lixia Huang, Lixiang Huang, Lixuan Huang, Lixue Huang, Lizhen Huang, Longfei Huang, Lu Huang, Lu-Jie Huang, Lu-Qi Huang, Luanluan Huang, Luqi Huang, Luyang Huang, Luyao Huang, Lvzhen Huang, M C Huang, Man Huang, Manning Y Huang, Manyun Huang, Mao-Mao Huang, Mei Huang, Meihua Huang, Meina Huang, Meixiang Huang, Melissa Y Huang, Meng-Chuan Huang, Meng-Fan Huang, Meng-Na Huang, MengQian Huang, Menghao Huang, Mengjie Huang, Mengjun Huang, Mengnan Huang, Mengting Huang, Mengzhen Huang, Mia L Huang, Miao Huang, Min Huang, Ming-Lu Huang, Ming-Shyan Huang, Mingjian Huang, Mingjun Huang, Minglei Huang, Mingrui Huang, Mingwei Huang, Mingxuan Huang, Mingyu Huang, Mingyuan Huang, Minjun Huang, Minqi Huang, Minxuan Huang, Minyuan Huang, N Huang, Na Huang, Nian Huang, Nianyuan Huang, Ning-Na Huang, Ning-Ping Huang, Ninghao Huang, Nongyu Huang, Pan Huang, Pang-Shuo Huang, Paul L Huang, Pei Huang, Pei-Chi Huang, Pei-Ying Huang, Peiying Huang, Peng Huang, Peng-Fei Huang, Pengyu Huang, Piao-Piao Huang, Piaopiao Huang, Pin-Rui Huang, Ping Huang, Pingping Huang, Pintong Huang, Po-Hsun Huang, Po-Jung Huang, Poyao Huang, Qi Huang, Qi-Tao Huang, Qian Huang, Qiang Huang, Qianqian Huang, Qiaobing Huang, Qibin Huang, Qidi Huang, Qin Huang, Qing Huang, Qing-yong Huang, Qingjiang Huang, Qingke Huang, Qingling Huang, Qingqing Huang, Qingsong Huang, Qingxia Huang, Qingxing Huang, Qingyu Huang, Qingzhi Huang, Qinlou Huang, Qiong Huang, Qiubo Huang, Qiumin Huang, Qiuming Huang, Qiuru Huang, Qiuyin Huang, Qiuyue Huang, Qizhen Huang, Quanfang Huang, Qun Huang, R H Huang, R Stephanie Huang, Rae-Chi Huang, Ran Huang, Renbin Huang, Renhua Huang, Renli Huang, Richard Huang, Richard S P Huang, Riqing Huang, Ritai Huang, Robert J Huang, Rong Huang, Rong Stephanie Huang, Ronghua Huang, Ronghui Huang, Rongjie Huang, Rongrong Huang, Rongxiang Huang, Ru-Ting Huang, Ruby Yun-Ju Huang, Rui Huang, Ruihua Huang, Ruijin Huang, Ruina Huang, Ruiyan Huang, Ruizhen Huang, Runyue Huang, Ruo-Hui Huang, S Huang, S Y Huang, S Z Huang, Saisai Huang, San-Yuan Huang, See-Chang Huang, Sen Huang, Shan Huang, Shang-Ming Huang, Shanhe Huang, Shanshan Huang, Shaojun Huang, Shaoxin Huang, Shaoze Huang, Shau Ku Huang, Shau-Ku Huang, Shenan Huang, Sheng-He Huang, Shengfeng Huang, Shengjie Huang, Shengnan Huang, Shengyan Huang, Shengyun Huang, Shi-Feng Huang, Shi-Shi Huang, Shi-Ying Huang, Shiang-Suo Huang, Shichao Huang, Shih-Chiang Huang, Shih-Wei Huang, Shih-Yi Huang, Shihao Huang, Shijing Huang, Shilu Huang, Shixia Huang, Shiya Huang, Shiying Huang, Shiyun Huang, Shoucheng Huang, Shu Huang, Shu-Pang Huang, Shu-Pin Huang, Shu-Qiong Huang, Shu-Wei Huang, Shu-Yi Huang, Shu-ying Huang, Shuai Huang, Shuang Huang, Shungen Huang, Shuo Huang, Shushu Huang, Shutong Huang, Shuwen Huang, Si-Yang Huang, Sidong Huang, Sihua Huang, Sijia Huang, Sinchun Huang, Sisi Huang, Sixiu Huang, Song Bin Huang, Song-Mei Huang, Songmei Huang, Songming Huang, Songqian Huang, Steven Huang, Steven Kuan-Hua Huang, Suli Huang, Sung-Ying Huang, Susan M Huang, Suwen Huang, Taiqi Huang, Tang-Hsiu Huang, Tao Huang, Te-Hsuan Huang, Tengda Huang, Tengfei Huang, Tian Hao Huang, Tianhao Huang, Tianpu Huang, Tiantian Huang, Tieqiu Huang, Tim H Huang, Ting Huang, Tinghua Huang, Tingping Huang, Tingqin Huang, Tingting Huang, Tingxuan Huang, Tingyun Huang, Tong Huang, Tongsheng Huang, Tongtong Huang, Tony T Huang, Tse-Shun Huang, Tseng-Yu Huang, Tsung-Wei Huang, Tzu-Rung Huang, Wan-Ping Huang, Way-Ren Huang, Wei Huang, Wei-Chi Huang, Weibin Huang, Weicheng Huang, Weifeng Huang, Weihua Huang, Weijun Huang, Weiqi Huang, Weisu Huang, Weiwei Huang, Weixue Huang, Weizhen Huang, Wen Huang, Wen-yu Huang, Wenbin Huang, Wenda Huang, Wenfang Huang, Wenfeng Huang, Wenhua Huang, Wenji Huang, Wenjie Huang, Wenjun Huang, Wenqiao Huang, Wenqing Huang, Wenqiong Huang, Wenshan Huang, Wentao Huang, Wenxin Huang, Wenya Huang, Wenying Huang, Wunan Huang, Wuqing Huang, X F Huang, X Huang, Xi Huang, Xian-sheng HUANG, Xiang Huang, Xianghua Huang, Xianglong Huang, Xiangming Huang, Xianping Huang, Xianqing Huang, Xiansheng Huang, Xianwei Huang, Xianxi Huang, Xianxian Huang, Xianying Huang, Xianzhang Huang, Xiao Huang, Xiao-Fang Huang, Xiao-Fei Huang, Xiao-Ming Huang, Xiao-Song Huang, Xiao-Yan Huang, Xiao-Yong Huang, Xiao-Yu Huang, XiaoFang Huang, Xiaochun Huang, Xiaofei Huang, Xiaofeng Huang, Xiaohong Huang, Xiaohua Huang, Xiaojie Huang, Xiaojing Huang, Xiaojuan Huang, Xiaolan Huang, Xiaoli Huang, Xiaolin Huang, Xiaoman Huang, Xiaomin Huang, Xiaoqing Huang, Xiaoshuai Huang, Xiaowen Huang, Xiaowu Huang, Xiaoxia Huang, Xiaoyan Huang, Xiaoying Huang, Xiaoyu Huang, Xiaoyuan Huang, Xiaoyun Huang, Xiaozhun Huang, Xiayang Huang, Xichang Huang, Xie-Lin Huang, Xin Huang, Xin-Di Huang, Xinen Huang, Xinfeng Huang, Xingguo Huang, Xingming Huang, Xingqin Huang, Xingru Huang, Xingxu Huang, Xingya Huang, Xingzhen Huang, Xinwen Huang, Xinyi Huang, Xinying Huang, Xinyue Huang, Xinzhu Huang, Xiongfeng Huang, Xionggao Huang, Xiuju Huang, Xiuyun Huang, Xiuzhen Huang, Xiwen Huang, Xu Huang, Xu-Feng Huang, Xuan Huang, Xuanzhang Huang, Xucong Huang, Xudong Huang, Xue-Ying Huang, Xue-shuang Huang, Xuehong Huang, Xuejie Huang, Xuejing Huang, Xuejun Huang, Xuemei Huang, Xueming Huang, Xueqi Huang, Xuewei Huang, Xuezhe Huang, Xuhui Huang, Xuliang Huang, Xun Huang, Xuxiong Huang, Y Huang, Y Joyce Huang, Y S Huang, Ya-Chih Huang, Ya-Dong Huang, Ya-Fang Huang, Ya-Ru Huang, Yabo Huang, Yadong Huang, Yafang Huang, Yajiao Huang, Yajuan Huang, Yali Huang, Yamei Huang, Yan Huang, Yan-Lin Huang, Yan-Qing Huang, Yan-Ting Huang, Yang Huang, Yang Zhong Huang, Yangqing Huang, Yangyang Huang, Yanhao Huang, Yani Huang, Yanjun Huang, Yanlong Huang, Yanna Huang, Yanping Huang, Yanqin Huang, Yanqing Huang, Yanqun Huang, Yanru Huang, Yanshan Huang, Yansheng Huang, Yanxia Huang, Yanyan Huang, Yanyao Huang, Yao Huang, Yao-Kuang Huang, Yaowei Huang, Yatian Huang, Yating Huang, Ye Huang, Yechao Huang, Yen-Chu Huang, Yen-Ning Huang, Yen-Tsung Huang, Yeqing Huang, Yewei Huang, Yi Huang, Yi-Chun Huang, Yi-Jan Huang, Yi-Jia Huang, Yi-Wen Huang, Yi-ping Huang, Yichao Huang, Yichuan Huang, Yicong Huang, Yifan Huang, Yihao Huang, Yiheng Huang, Yihong Huang, Yikeng Huang, Yilin Huang, Yin Huang, Yin-Tsen Huang, Ying Huang, Ying-Hsuan Huang, Ying-Jung Huang, Ying-Zhi Huang, Yinghua Huang, Yingying Huang, Yingzhen Huang, Yingzhi Huang, Yiping Huang, Yiquan Huang, Yishan Huang, Yiwei Huang, Yixian Huang, Yizhou Huang, Yong Huang, Yong-Fu Huang, Yongbiao Huang, Yongcan Huang, Yongjie Huang, Yongqi Huang, Yongsheng Huang, Yongtong Huang, Yongye Huang, Yongyi Huang, Yongzhen Huang, Youheng Huang, Youyang Huang, Yu Huang, Yu-Ching Huang, Yu-Chu Huang, Yu-Chuen Huang, Yu-Chyi Huang, Yu-Fang Huang, Yu-Han Huang, Yu-Jie Huang, Yu-Lei Huang, Yu-Ren Huang, Yu-Shu Huang, Yu-Ting Huang, Yuan Huang, Yuan-Lan Huang, Yuan-Li Huang, Yuan-Lu Huang, Yuancheng Huang, Yuanpeng Huang, Yuanshuai Huang, Yuanyu Huang, Yuanyuan Huang, Yue Huang, Yue-Hua Huang, Yuedi Huang, Yueh-Hsiang Huang, Yuehong Huang, Yuejun Huang, Yueye Huang, Yuezhen Huang, Yufang Huang, Yufen Huang, Yuguang Huang, Yuh-Chin T Huang, Yuhong Huang, Yuhua Huang, Yuhui Huang, Yujia Huang, Yujie Huang, Yulin Huang, Yumei Huang, Yumeng Huang, Yun Huang, Yun-Juan Huang, Yunchao Huang, Yung-Hsin Huang, Yung-Yu Huang, Yunmao Huang, Yunpeng Huang, Yunru Huang, Yunyan Huang, Yuping Huang, Yuqi Huang, Yuqiang Huang, Yuqiong Huang, Yusi Huang, Yutang Huang, Yuting Huang, Yutong Huang, Yuxian Huang, Yuxin Huang, Yuxuan Huang, Yuyang Huang, Yuying Huang, Z Huang, Z Z Huang, Z-Y Huang, Zebin Huang, Zebo Huang, Zehua Huang, Zeling Huang, Zengwen Huang, Zhang Huang, Zhao Huang, Zhaoxia Huang, Zhe Huang, Zhen Huang, Zhenfei Huang, Zheng Huang, Zheng-Xiang Huang, Zhengwei Huang, Zhengxian Huang, Zhengxiang Huang, Zhengyang Huang, Zhenlin Huang, Zhenrui Huang, Zhenyao Huang, Zhenyi Huang, Zhi Huang, Zhi-Ming Huang, Zhi-Qiang Huang, Zhi-Xin Huang, Zhi-xiang Huang, Zhican Huang, Zhicong Huang, Zhifang Huang, Zhifeng Huang, Zhigang Huang, Zhihong Huang, Zhilin Huang, Zhilong Huang, Zhipeng Huang, Zhiping Huang, Zhiqi Huang, Zhiqiang Huang, Zhiqin Huang, Zhiqing Huang, Zhitong Huang, Zhiwei Huang, Zhixiang Huang, Zhiying Huang, Zhiyong Huang, Zhiyu Huang, Zhongbin Huang, Zhongcheng Huang, Zhongfeng Huang, Zhonglu Huang, Zhouyang Huang, Zi-Xin Huang, Zi-Ye Huang, Zicheng Huang, Zichong Huang, Zihan Huang, Zihao Huang, Ziheng Huang, Ziling Huang, Zini Huang, Zirui Huang, Zizhan Huang, Zongjian Huang, Zongliang Huang, Zunnan Huang, Zuotian Huang, Zuxian Huang, Zuyi Huang
articles
Xiao-Ming Huang, Wan-Chen Yang, Yang Liu +3 more · 2020 · Experimental biology and medicine (Maywood, N.J.) · SAGE Publications · added 2026-04-24
The detailed molecular mechanism of orbital venous malformation (OVM) is still not clear. Using whole exome sequencing, 4 types of melanocortin 4 receptor (MC4R) mutation were detected in 7 of 27 pati Show more
The detailed molecular mechanism of orbital venous malformation (OVM) is still not clear. Using whole exome sequencing, 4 types of melanocortin 4 receptor (MC4R) mutation were detected in 7 of 27 patients with OVM, and all types of MC4R mutations resulted in the upregulation of MC4R expression. Show less
no PDF DOI: 10.1177/1535370220919056
MC4R
Yaling Zhu, Qingjie Zeng, Fang Li +8 more · 2020 · Frontiers in genetics · Frontiers · added 2026-04-24
Epigenetic regulation of gene expression has been reported in the pathogenesis of metabolic disorders such as diabetes and liver steatosis in humans. However, the molecular mechanisms of fatty liver h Show more
Epigenetic regulation of gene expression has been reported in the pathogenesis of metabolic disorders such as diabetes and liver steatosis in humans. However, the molecular mechanisms of fatty liver hemorrhagic syndrome (FLHS) in chickens have been rarely studied. H3K27ac chromatin immunoprecipitation coupled with high-throughput sequencing and high-throughput RNA sequencing was performed to compare genome-wide H3K27ac profiles and transcriptomes of liver tissue between healthy and FLHS chickens. In total, 1,321 differential H3K27ac regions and 443 differentially expressed genes were identified (| log2Fold change| ≥ 1 and Show less
📄 PDF DOI: 10.3389/fgene.2020.574167
ANGPTL4
Yezi Kong, Chenxu Zhao, Yan Huang +7 more · 2020 · IUBMB life · Wiley · added 2026-04-24
In dairy cows, fatty liver is one of the most common metabolic diseases that occurs during the periparturient period. Angiopoietin-like protein 4 (ANGPTL4) is a well-known downstream target of peroxis Show more
In dairy cows, fatty liver is one of the most common metabolic diseases that occurs during the periparturient period. Angiopoietin-like protein 4 (ANGPTL4) is a well-known downstream target of peroxisome proliferator-activated receptors (PPARs), which regulate the glucose and fatty acid metabolisms. The inhibition of lipoprotein lipase (LPL) activity interferes with the storage of triglycerides (TG) in adipocytes, which plays an essential role in lipid metabolism in rodents. However, it remains unclear whether ANGPTL4 is involved in the pathological process of fatty liver in dairy cows as a result of the regulation of the hepatocellular lipid transport system. This study intended to investigate the effect of ANGPTL4 on the very-low-density lipoprotein (VLDL) assembly and secretion in bovine hepatocytes. Bovine hepatocytes were isolated using a modified two-step perfusion and collagenase digestion process, and treated with different concentrations of ANGPTL4 (0, 4, 12, and 24 ng/ml) for 24 hr. The results showed that a high concentration of ANGPTL4 could significantly increase the extracellular concentration of VLDL while reducing the intracellular content of TG. Thus, it was confirmed that ANGPTL4 could promote the transport of TG in the form of VLDL by partially regulating the expression of related proteins in hepatocytes, thereby contributing to the partial adaptive regulation of lipid transport in dairy cows. Show less
no PDF DOI: 10.1002/iub.2403
ANGPTL4
William Yang, Elie Khoury, Qianyu Guo +10 more · 2020 · Oncogene · Nature · added 2026-04-24
The BRAF
📄 PDF DOI: 10.1038/s41388-020-1240-5
ANGPTL4
Yuting Li, Yuxing Chen, Xuejun Huang +9 more · 2020 · Lipids · Wiley · added 2026-04-24
Tanshinol A, which is derived from a traditional Chinese herbal Radix Salviae Miltiorrhizae is indicative of a hypolipidemic candidate. Therefore, we aim to validate its hypolipidemic activity of tans Show more
Tanshinol A, which is derived from a traditional Chinese herbal Radix Salviae Miltiorrhizae is indicative of a hypolipidemic candidate. Therefore, we aim to validate its hypolipidemic activity of tanshinol A and explore its mechanism in triton-1339W-induced hyperlipidemic mice model, which possess multiply pathogenesis for endogenous lipid metabolism disorder. Experimental hyperlipidemia mice are treated with or without tanshinol A (i.g. 40, 20, 10 mg/kg), and blood and liver tissue were collected for validating its hypolipidemic and hepatic protective effect, and hepatic mRNA expression profile, which was associated with lipid metabolism dysfunction and liver injury, was detected by RT-qPCR. As results show, triton-1339W-induced abnormal of serum TC, TAG, HDL-C, LDL-C, SOD, MDA, GOT, and GPT is remarkably attenuated by tanshinol A. In pathological experiment, triton-1339W-induced hepatocellular ballooning degeneration, irregular central vein congestion, and inflammation infiltration are alleviated by tanshinol A. Correspondingly, hepatic mRNA expression of Atf4, Fgf21, Vldlr, Nqo1, Pdk4, and Angptl4, which are genes regulating lipemic-oxidative injury, are significantly increased by tanshinol A by 2~6 fold. Abcg5, Cd36, and Apob, which are responsible for cholesterol metabolism, are mildly upregulated. Noticeably, triton-1339W-suppressed expressions of Ptgs2/Il10, which are genes responsible for acute inflammation resolution in liver injury, are remarkably increased by tanshinol A. Conclusively, tanshinol A exerted hypolipidemic effect and hepatoprotective effect through restoring triton-1339W-suppressed mRNA expression, which may be involved in Atf4/Fgf21/Vldlr and Ptgs2/Il-10 signaling pathways. Show less
no PDF DOI: 10.1002/lipd.12217
ANGPTL4
Jing Li, Liang Li, DongMing Guo +6 more · 2020 · Clinica chimica acta; international journal of clinical chemistry · Elsevier · added 2026-04-24
Hypertriglyceridemia is a risk factor for a series of diseases, such as cardiovascular disease (CVD), diabetes and nonalcoholic fatty liver disease (NAFLD). Angiopoietin-like proteins (ANGPTLs) family Show more
Hypertriglyceridemia is a risk factor for a series of diseases, such as cardiovascular disease (CVD), diabetes and nonalcoholic fatty liver disease (NAFLD). Angiopoietin-like proteins (ANGPTLs) family, especially ANGPTL3, ANGPTL4 and ANGPTL8, which regulate lipoprotein lipase (LPL) activity, play pivotal roles in triglyceride (TG) metabolism and related diseases/complications. There are many transcriptional and post-transcriptional factors that participate in physiological and pathological regulation of ANGPTLs to affect triglyceride metabolism. This review is intended to focus on the similarity and difference in the expression, structural features, regulation profile of the three ANGPTLs and inhibitory models for LPL. Description of the regulatory factors of ANGPTLs and the properties in regulating the lipid metabolism involved in the underlying mechanisms in pathological effects on diseases will provide potential therapeutic approaches for the treatment of dyslipidemia related diseases. Show less
no PDF DOI: 10.1016/j.cca.2019.12.029
ANGPTL4
Wen-Hsuan Yang, Zhiqing Huang, Jianli Wu +3 more · 2020 · Molecular cancer research : MCR · added 2026-04-24
Ovarian cancer is the deadliest gynecologic cancer. Despite recent advances, clinical outcomes remain poor, necessitating novel therapeutic approaches. To investigate metabolic susceptibility, we perf Show more
Ovarian cancer is the deadliest gynecologic cancer. Despite recent advances, clinical outcomes remain poor, necessitating novel therapeutic approaches. To investigate metabolic susceptibility, we performed nutrigenetic screens on a panel of clear cell and serous ovarian cancer cells and identified cystine addiction and vulnerability to ferroptosis, a novel form of regulated cell death. Our results may have therapeutic potential, but little is known about the determinants of ferroptosis susceptibility in ovarian cancer. We found that vulnerability to ferroptosis in ovarian cancer cells is enhanced by lower cell confluency. Because the Hippo pathway effectors Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) are recognized as sensors of cell density, and TAZ is the predominant effector in the tested ovarian cancer cell lines, we investigated the role of TAZ in ferroptosis of ovarian cancer. TAZ removal confers ferroptosis resistance, while TAZS89A overexpression sensitizes cells to ferroptosis. In addition, we found that lower TAZ level in chemo-resistant recurrent ovarian cancer is responsible for reduced ferroptosis susceptibility. The integrative genomic analysis identified ANGPTL4 as a direct TAZ-regulated target gene that sensitizes ferroptosis by activating NOX2. Collectively, cell density-regulated ferroptosis in ovarian cancer is mediated by TAZ through the regulation of the ANGPTL4-NOX2 axis, suggesting therapeutic potentials for ovarian cancers and other TAZ-activated tumors. IMPLICATIONS: This study reveals that TAZ promotes ferroptosis in ovarian cancers by regulating ANGPTL4 and NOX, offering a novel therapeutic potential for ovarian tumors with TAZ activation. Show less
📄 PDF DOI: 10.1158/1541-7786.MCR-19-0691
ANGPTL4
Junhe Zhou, Lin Zhao, Lingcui Meng +7 more · 2020 · Trials · BioMed Central · added 2026-04-24
Carotid atherosclerosis disease (CAD) is generally associated with the occurrence of cardiovascular and cerebrovascular accidents. However, CAD has not been taken seriously enough in the clinic, which Show more
Carotid atherosclerosis disease (CAD) is generally associated with the occurrence of cardiovascular and cerebrovascular accidents. However, CAD has not been taken seriously enough in the clinic, which, coupled with the single treatment and prevention of CAD, has led to a generally low level of patient compliance. Therefore, acupuncture is expected to be a safe and effective therapy that can be maintained in the long term for patients with CAD. The study objective is to evaluate the efficiency and reliability of acupuncture to relieve CAD and provide a new therapeutic idea for the clinical treatment of CAD. This is a three-arm randomized clinical trial in China. Three groups (TA, SA, and MC) will be randomly allocated at a 1:1:1 ratio. The study will enrol 105 cervical atherosclerosis plaque patients in total on a voluntary basis, with 35 patients in each group. The treatment will last for 12 weeks, with two treatments per week for twenty-four treatments in total. Two 3D ultrasound indicators will be measured as the primary outcomes: the total plaque volume (PV) of the carotid artery on each side and the grey-scale median (GSM). The secondary outcomes will include intima-media thickness (IMT), lipid levels, apolipoprotein A-IV level, platelet count (PLT), fibrinogen (FIB), and platelet aggregation rate (PAR). All the outcomes will be assessed before treatment, after treatment, and after a 12-week follow-up period. This study will utilize per-protocol (PP) and intention-to-treat (ITT) analysis principles. This trial is to evaluate the efficacy and reliability of acupuncture in relieving carotid atherosclerotic plaques by establishing acupuncture (TA), sham acupuncture (SA), and medication (MC) groups. This study was approved by the Institutional Ethics Committee of Guangdong Provincial Hospital of Traditional Chinese Medicine (no. YF2018-107-01). All data and findings will be provided by the principal investigator via email. ChiCTR, ChiCTR1800019259 . Registered on 1 November 2018-retrospectively registered, http://www.chictr.org.cn/index.aspx. Show less
📄 PDF DOI: 10.1186/s13063-020-04709-0
APOA4
Weihua Shou, Chenhui Zhang, Jinxiu Shi +2 more · 2020 · Journal of genetics and genomics = Yi chuan xue bao · Elsevier · added 2026-04-24
The unusual chromosome 11q23.3 harboring the apolipoprotein (APO) gene cluster has been well documented for its essential roles in plasma lipid-related traits and atherosclerotic cardiovascular diseas Show more
The unusual chromosome 11q23.3 harboring the apolipoprotein (APO) gene cluster has been well documented for its essential roles in plasma lipid-related traits and atherosclerotic cardiovascular diseases. However, its genetic architecture and the potential biological mechanisms underlying complex phenotypes have not been well assessed. We conducted a study for this target region in a Han Chinese population through a stepwise forward framework based on massive parallel sequencing, association analyses, genetic fine mapping, and functional interpretation. The present study identified new meaningful genetic associations that were not simply determined by statistical significance. In addition to the APOA5 gene, we found robust evidence of the genetic commitments of APOC3 and APOA1 to blood lipids. Several variants with high confidence were prioritized along with the potential biological mechanism interpretations in the wake of adaptive fine-mapping analyses. rs2849174 in the APOC3 enhancer was discovered with an unrivaled posterior probability of causality for triglyceride levels and could mediate APOC3 expression through enhancer activity modulated by a combination of histone modifications and transcription factor accessibility. Similarly, multiple lines of evidence converged in favor of rs3741297 as a causal variant influencing high-density lipoprotein cholesterol. Our findings provided novel insights into this genomic locus in the Chinese population. Show less
no PDF DOI: 10.1016/j.jgg.2020.11.010
APOA5
Xiaoyun Cheng, Yueye Huang, Peng Yang +1 more · 2020 · Life sciences · Elsevier · added 2026-04-24
Islet beta-cell dysfunction is an important condition leading to the development of diabetes. Numerous studies have found that miRNA regulates islet β-cell function. In our previous research, the aber Show more
Islet beta-cell dysfunction is an important condition leading to the development of diabetes. Numerous studies have found that miRNA regulates islet β-cell function. In our previous research, the aberrant expression of miR-383 was revealed in type 2 diabetes mellitus (T2DM) serum. Herein, we aimed to assess the function and underlying mechanism of miR-383 in β-cells through in vitro and in vivo experiments. Using high glucose media, the β-cell injury was induced and transfected miR-383 overexpression vector to detect cell function in MIN6. Moreover, miR-383 overexpression lentivirus was administrated into high-fat induced diabetes mice to assess the in vivo effect. Results showed that overexpressing miR-383 reversed the cell apoptosis and oxidative stress, induced by high glucose which targets Toll-like receptors (TLR4) and Apolipoprotein C3 (ApoC3) genes. Furthermore, mechanistic studies demonstrated that miR-383 targeted the TLR4 and ApoC3 3' UTR consequently inhibiting TLR4 and ApoC3 expression in MIN6 cells. Besides, overexpression of miR-383 ameliorated hyperglycemia and pancreatic apoptosis in high-fat induced diabetic mice. Conclusively, miR-383 potentially alleviate pancreatic β-cell injury induced by high glucose and ameliorates high-fat induced diabetes by suppressing TLR4 and ApoC3 expression. Show less
no PDF DOI: 10.1016/j.lfs.2020.118571
APOC3
Jing Gong, Hong-Xia Wang, Yeh-Hsing Lao +8 more · 2020 · Advanced materials (Deerfield Beach, Fla.) · Wiley · added 2026-04-24
Recent advances in CRISPR present attractive genome-editing toolsets for therapeutic strategies at the genetic level. Here, a liposome-coated mesoporous silica nanoparticle (lipoMSN) is reported as an Show more
Recent advances in CRISPR present attractive genome-editing toolsets for therapeutic strategies at the genetic level. Here, a liposome-coated mesoporous silica nanoparticle (lipoMSN) is reported as an effective CRISPR delivery system for multiplex gene-editing in the liver. The MSN provides efficient loading of Cas9 plasmid as well as Cas9 protein/guide RNA ribonucleoprotein complex (RNP), while liposome-coating offers improved serum stability and enhanced cell uptake. Hypothesizing that loss-of-function mutation in the lipid-metabolism-related genes pcsk9, apoc3, and angptl3 would improve cardiovascular health by lowering blood cholesterol and triglycerides, the lipoMSN is used to deliver a combination of RNPs targeting these genes. When targeting a single gene, the lipoMSN achieved a 54% gene-editing efficiency, besting the state-of-art Lipofectamine CRISPRMax. For multiplexing, lipoMSN maintained significant gene-editing at each gene target despite reduced dosage of target-specific RNP. By delivering combinations of targeting RNPs in the same nanoparticle, synergistic effects on lipid metabolism are observed in vitro and vivo. These effects, such as a 50% decrease in serum cholesterol after 4 weeks of post-treatment with lipoMSN carrying both pcsk9 and angptl3-targeted RNPs, could not be reached with a single gene-editing approach. Taken together, this lipoMSN represents a versatile platform for the development of efficient, combinatorial gene-editing therapeutics. Show less
📄 PDF DOI: 10.1002/adma.202003537
APOC3
Meixiang Huang, Erica Modeste, Eric Dammer +9 more · 2020 · Acta neuropathologica communications · BioMed Central · added 2026-04-24
Heterozygous, loss-of-function mutations in the granulin gene (GRN) encoding progranulin (PGRN) are a common cause of frontotemporal dementia (FTD). Homozygous GRN mutations cause neuronal ceroid lipo Show more
Heterozygous, loss-of-function mutations in the granulin gene (GRN) encoding progranulin (PGRN) are a common cause of frontotemporal dementia (FTD). Homozygous GRN mutations cause neuronal ceroid lipofuscinosis-11 (CLN11), a lysosome storage disease. PGRN is a secreted glycoprotein that can be proteolytically cleaved into seven bioactive 6 kDa granulins. However, it is unclear how deficiency of PGRN and granulins causes neurodegeneration. To gain insight into the mechanisms of FTD pathogenesis, we utilized Tandem Mass Tag isobaric labeling mass spectrometry to perform an unbiased quantitative proteomic analysis of whole-brain tissue from wild type (Grn Show less
📄 PDF DOI: 10.1186/s40478-020-01037-x
APOC3
Mengmeng Guo, Yitong Xu, Zhao Dong +7 more · 2020 · Circulation research · added 2026-04-24
no PDF DOI: 10.1161/CIRCRESAHA.120.317686
APOC3
Bing Shu, Yongjian Zhao, Shitian Zhao +12 more · 2020 · Bone research · Nature · added 2026-04-24
Axin1 is a negative regulator of β-catenin signaling and its role in osteoblast precursor cells remains undefined. In the present studies, we determined changes in postnatal bone growth by deletion of
📄 PDF DOI: 10.1038/s41413-020-0104-5
AXIN1
Dan Wen, Rong Huang, Jianping Xie +2 more · 2020 · Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology · added 2026-04-24
Objective To construct the axis inhibition protein 1 (AXIN1) gene-knockout ACT-1 human undifferentiated thyroid cancer single clone cell line. Methods Molecular cloning technology and clustered regula Show more
Objective To construct the axis inhibition protein 1 (AXIN1) gene-knockout ACT-1 human undifferentiated thyroid cancer single clone cell line. Methods Molecular cloning technology and clustered regularly interspaced short palindromic repeats/Cas9 nuclease (CRISPR/Cas9) were used to construct AXIN1 gene-knockout single clone cell lines. Real-time quantitative PCR and Western blotting were used to detect AXIN1 mRNA and protein levels of ACT-1 cells, respectively. Results T7 detection results showed two effective single guide RNAs (sgRNAs) Cr3 and Cr5 were successfully constructed; enzyme digestion identification and sequencing showed AXIN1-targeted sgRNA viral vectors carrying green fluorescent protein (GFP) were successfully constructed. We successfully obtained 4 monoclonal ACT-1 undifferentiated thyroid cancer cell lines. AXIN1 mRNA and protein levels in the gene-knockout group were significantly reduced. Conclusion The ACT-1 undifferentiated thyroid cancer cell line with AXIN1 gene knockout has been successfully constructed using CRISPR/Cas9. Show less
no PDF
AXIN1
Tong Huang, Qingquan Zhang, Wei Ren +5 more · 2020 · Cell biology international · Wiley · added 2026-04-24
Colorectal cancer (CRC) is the leading cause of cancer death, and its 5-year survival rate remains unsatisfactory. Recent studies have revealed that ubiquitin-specific protease 44 (USP44) is a cancer Show more
Colorectal cancer (CRC) is the leading cause of cancer death, and its 5-year survival rate remains unsatisfactory. Recent studies have revealed that ubiquitin-specific protease 44 (USP44) is a cancer suppressor or oncogene depending on the type of neoplasm. However, its role in CRC remains unclear. Here, we found that the USP44 expression level was markedly decreased in CRC, and USP44 overexpression inhibited proliferation while enhancing apoptosis in CRC cells, suggesting that USP44 is a cancer suppressor in CRC. We then investigated if USP44 functioned through regulating the Wnt/β-catenin pathway. We found that USP44 overexpression increased the Axin1 protein while decreasing β-catenin, c-myc, and cyclin D1 proteins, suggesting that USP44 inhibited the activation of the Wnt/β-catenin pathway. Moreover, we found that two Wnt/β-catenin activators, LiCl and SKL2001, both attenuated oeUSP44-mediated proliferation and apoptosis in CRC cells. Collectively, these data points indicated that USP44 inhibited proliferation while promoting apoptosis in CRC cells by inhibiting the Wnt/β-catenin pathway. Interestingly, we observed that USP44 overexpression did not affect the Axin1 mRNA level. Further study uncovered that USP44 interacted with Axin1 and reduced the ubiquitination of Axin1. Furthermore, Axin1 knock-down abolished the effects of oeUSP44 on proliferation, apoptosis, and Wnt/β-catenin activity in CRC cells. Taken together, this study demonstrates that USP44 inhibits proliferation while enhancing apoptosis in CRC cells by inactivating the Wnt/β-catenin pathway via Axin1 deubiquitination. USP44 is a cancer suppressor in CRC and a potential target for CRC therapy. Show less
📄 PDF DOI: 10.1002/cbin.11358
AXIN1
Ancheng Qin, Jianwu Wu, Min Zhai +5 more · 2020 · American journal of translational research · added 2026-04-24
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with a high mortality rate and low survival rate. This study was designed to explore a novel molecular with high sensitivity a Show more
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with a high mortality rate and low survival rate. This study was designed to explore a novel molecular with high sensitivity and specificity, which can be applied in early diagnosis and therapeutic evaluation of HCC. The current study aims to investigate the effect and important role of Axin1 on cell proliferation, invasion, migration and epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma. qRT-PCR results showed lower Axin1 expression level and higher miR-650 expression level in HCC. Luciferase reporter assay was carried out to verify the negative correlation between Axin1 and miR-650 mRNA levels. CCK-8 assay results showed that the cell proliferation ability was significantly suppressed by Axin1 overexpression in SK-HEP-1 cells. The results in wound healing assay uncovered that cell migration ability was markedly suppressed by Axin1 overexpression. The results in trans-well invasion assay showed that Axin1 overexpression caused decreased invasive ability in SK-HEP-1 cells. The WB results showed that the protein level of E-cad was significantly increased and the protein levels of N-cad, vimentin and snail were obviously reduced following Axin1 overexpression. Whereas, the suppressive effects on cell proliferation, migration, invasion and EMT caused by Axin1 overexpression were abolished by miR-650 mimic. All the results in the current study confirmed the truth that Axin1 overexpression could suppress cell proliferation, migration, invasion and EMT by downregulating miR-650 expression. Show less
no PDF
AXIN1
Jiansheng Huang, Dongdong Wang, Li-Hao Huang +1 more · 2020 · International journal of molecular sciences · MDPI · added 2026-04-24
Epidemiological results revealed that there is an inverse correlation between high-density lipoprotein (HDL) cholesterol levels and risks of atherosclerotic cardiovascular disease (ASCVD). Mounting ev Show more
Epidemiological results revealed that there is an inverse correlation between high-density lipoprotein (HDL) cholesterol levels and risks of atherosclerotic cardiovascular disease (ASCVD). Mounting evidence supports that HDLs are atheroprotective, therefore, many therapeutic approaches have been developed to increase HDL cholesterol (HDL-C) levels. Nevertheless, HDL-raising therapies, such as cholesteryl ester transfer protein (CETP) inhibitors, failed to ameliorate cardiovascular outcomes in clinical trials, thereby casting doubt on the treatment of cardiovascular disease (CVD) by increasing HDL-C levels. Therefore, HDL-targeted interventional studies were shifted to increasing the number of HDL particles capable of promoting ATP-binding cassette transporter A1 (ABCA1)-mediated cholesterol efflux. One such approach was the development of reconstituted HDL (rHDL) particles that promote ABCA1-mediated cholesterol efflux from lipid-enriched macrophages. Here, we explore the manipulation of rHDL nanoparticles as a strategy for the treatment of CVD. In addition, we discuss technological capabilities and the challenge of relating preclinical in vivo mice research to clinical studies. Finally, by drawing lessons from developing rHDL nanoparticles, we also incorporate the viabilities and advantages of the development of a molecular imaging probe with HDL nanoparticles when applied to ASCVD, as well as gaps in technology and knowledge required for putting the HDL-targeted therapeutics into full gear. Show less
📄 PDF DOI: 10.3390/ijms21030739
CETP
Jian Zhu, Sen Wei, Linchen Huang +3 more · 2020 · Journal of molecular graphics & modelling · Elsevier · added 2026-04-24
The human plasma cholesteryl ester transfer protein (CETP) collects triglycerides from very-/low-density lipoproteins (V/LDL) and exchanges them for cholesteryl esters from high-density lipoproteins ( Show more
The human plasma cholesteryl ester transfer protein (CETP) collects triglycerides from very-/low-density lipoproteins (V/LDL) and exchanges them for cholesteryl esters from high-density lipoproteins (HDL), which has recognized as an important therapeutic target for atherosclerosis. The protein has a C-terminal amphipathic α-helix that serves as self-binding peptide to fulfill biological function by dynamically binding to/unbinding from its cognate site (termed self-binding site) in the same protein. Previously, we successfully derived and halogenated the helical peptide to competitively disrupt the self-binding behavior of CETP C-terminal tail. However, the halogenated peptides have only a limited affinity increase as compared to native helical peptide (∼3-fold), thus exhibiting only a moderate competitive potency. Here, instead of optimizing the direct intermolecular interaction of peptide with CETP self-binding site we attempt to further improve the peptide competitive potency by reducing its conformational flexibility with hydrocarbon-stapling technique. Computational analysis reveals that the helical peptide has large intrinsic disorder in unbound free state, which would incur a considerable entropy penalty upon rebinding to the self-binding site. All-hydrocarbon bridge is designed and optimized on native and halogenated peptides in terms of the helical pattern and binding mode of self-binding peptide. Dynamics simulation and circular dichroism indicate that the stapling can considerably reduce peptide disorder in free state. Energetics calculation and fluorescence assay conform that the binding affinity of stapled/halogenated peptides is improved substantially (by > 5-fold), thus exhibiting an effective competition potency with native peptide for the self-binding site. Structural examination suggests that the binding modes and nonbonded interactions of native and halogenated peptides are not influenced essentially due to the stapling. Show less
no PDF DOI: 10.1016/j.jmgm.2019.107455
CETP
Qingnv Zhou, Huafei Huang, Li Ma +1 more · 2020 · BioMed research international · added 2026-04-24
During Jan. 2016-Dec. 2019, nine Chinese patients from eight unrelated families were diagnosed with neonatal-onset UCDs by targeted panel sequencing or whole-exome sequencing (WES). Their clinical man Show more
During Jan. 2016-Dec. 2019, nine Chinese patients from eight unrelated families were diagnosed with neonatal-onset UCDs by targeted panel sequencing or whole-exome sequencing (WES). Their clinical manifestations, biochemical features, 180-day-age outcomes, and molecular genetic characteristics were reviewed retrospectively. NGS-based tests revealed 7 patients diagnosed with ornithine transcarbamylase deficiency (OTCD) and 2 with carbamoylphosphate synthetase I deficiency (CPS1D). The spectrum of the clinical presentation of nine affected individuals progressed from unspecific symptoms like poor feeding to somnolence, coma, and death. All patients presented with an acute hyperammonemia. The most robust metabolic pattern in OTCD was hyperglutaminemic hyperammonemia with high concentration of urine orotic acid, and it was reported in six patients. Of ten variants found on the Show less
📄 PDF DOI: 10.1155/2020/5690915
CPS1
Ting Gang Chew, Tzer Chyn Lim, Yumi Osaki +5 more · 2020 · Molecular biology of the cell · American Society for Cell Biology · added 2026-04-24
Eukaryotic cells assemble actomyosin rings during cytokinesis to function as force-generating machines to drive membrane invagination and to counteract the intracellular pressure and the cell surface Show more
Eukaryotic cells assemble actomyosin rings during cytokinesis to function as force-generating machines to drive membrane invagination and to counteract the intracellular pressure and the cell surface tension. How the extracellular matrix affects actomyosin ring contraction has not been fully explored. While studying the Show less
📄 PDF DOI: 10.1091/mbc.E20-04-0245
CPS1
Jun Xu, Aimin Zhang, Furong Huang · 2020 · Experimental and therapeutic medicine · added 2026-04-24
The aim of the present report was to describe the clinical presentation, diagnosis, and treatment of a case of carbamoyl phosphate synthetase 1 (CPS1) deficiency in a neonate, specifically, a 3 day-ol Show more
The aim of the present report was to describe the clinical presentation, diagnosis, and treatment of a case of carbamoyl phosphate synthetase 1 (CPS1) deficiency in a neonate, specifically, a 3 day-old female who visited Hunan Provincial People's Hospital due to anorexia and lethargy for 1 day. Physical and laboratory examination, and MRI were undertaken. Whole exome sequencing (WES) was applied for molecular etiology identification. Sanger sequencing was utilized to validate the variants detected by WES. Structural modeling was conducted for pathogenic analysis. Clinical examination revealed increased intracranial pressure, hyperammonemia, reduced citrulline, and increased glutamic acid levels. WES identified compound heterozygosity of c.713G>C, p.Arg238Pro and c.2339G>A, p.Arg780His in Show less
no PDF DOI: 10.3892/etm.2020.8717
CPS1
Shihua Yao, Tuong-Vi Nguyen, Alan Rolfe +17 more · 2020 · Cell chemical biology · Elsevier · added 2026-04-24
Carbamoyl phosphate synthetase 1 (CPS1) catalyzes the first step in the ammonia-detoxifying urea cycle, converting ammonia to carbamoyl phosphate under physiologic conditions. In cancer, CPS1 overexpr Show more
Carbamoyl phosphate synthetase 1 (CPS1) catalyzes the first step in the ammonia-detoxifying urea cycle, converting ammonia to carbamoyl phosphate under physiologic conditions. In cancer, CPS1 overexpression supports pyrimidine synthesis to promote tumor growth in some cancer types, while in others CPS1 activity prevents the buildup of toxic levels of intratumoral ammonia to allow for sustained tumor growth. Targeted CPS1 inhibitors may, therefore, provide a therapeutic benefit for cancer patients with tumors overexpressing CPS1. Herein, we describe the discovery of small-molecule CPS1 inhibitors that bind to a previously unknown allosteric pocket to block ATP hydrolysis in the first step of carbamoyl phosphate synthesis. CPS1 inhibitors are active in cellular assays, blocking both urea synthesis and CPS1 support of the pyrimidine biosynthetic pathway, while having no activity against CPS2. These newly discovered CPS1 inhibitors are a first step toward providing researchers with valuable tools for probing CPS1 cancer biology. Show less
no PDF DOI: 10.1016/j.chembiol.2020.01.009
CPS1
Yan Gao, Hui Li, Qing Han +10 more · 2020 · Journal of Cancer · added 2026-04-24
📄 PDF DOI: 10.7150/jca.37267
DUSP6
Yuan Zhang, Longfei Du, Ying Bai +15 more · 2020 · Molecular psychiatry · Nature · added 2026-04-24
Circular RNAs (circRNAs), highly expressed in the central nervous system, are involved in various regulatory processes and implicated in some pathophysiology. However, the potential role of circRNAs i Show more
Circular RNAs (circRNAs), highly expressed in the central nervous system, are involved in various regulatory processes and implicated in some pathophysiology. However, the potential role of circRNAs in psychiatric diseases, particularly major depressive disorder (MDD), remains largely unknown. Here, we demonstrated that circular RNA DYM (circDYM) levels were significantly decreased both in the peripheral blood of patients with MDD and in the two depressive-like mouse models: the chronic unpredictable stress (CUS) and lipopolysaccharide (LPS) models. Restoration of circDYM expression significantly attenuated depressive-like behavior and inhibited microglial activation induced by CUS or LPS treatment. Further examination indicated that circDYM functions as an endogenous microRNA-9 (miR-9) sponge to inhibit miR-9 activity, which results in a downstream increase of target-HECT domain E3 ubiquitin protein ligase 1 (HECTD1) expression, an increase of HSP90 ubiquitination, and a consequent decrease of microglial activation. Taken together, the results of our study demonstrate the involvement of circDYM and its coupling mechanism in depression, providing translational evidence that circDYM may be a novel therapeutic target for depression. Show less
📄 PDF DOI: 10.1038/s41380-018-0285-0
DYM
Xiao Wang, Chengfeng Ding, Wenxia Yu +15 more · 2020 · Cell reports · Elsevier · added 2026-04-24
The advent of base editors (BEs) holds great potential for correcting pathogenic-related point mutations to treat relevant diseases. However, Cas9 nickase (nCas9)-derived BEs lead to DNA double-strand Show more
The advent of base editors (BEs) holds great potential for correcting pathogenic-related point mutations to treat relevant diseases. However, Cas9 nickase (nCas9)-derived BEs lead to DNA double-strand breaks, which can trigger unwanted DNA damage response (DDR). Here, we show that the original version of catalytically dead Cas12a (dCas12a)-conjugated BEs induce a basal level of DNA breaks and minimally activate DDR proteins, including H2AX, ATM, ATR, and p53. By fusing dCas12a with engineered human apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A (APOBEC3A), we further develop the BEACON (base editing induced by human APOBEC3A and Cas12a without DNA break) system to achieve enhanced deamination efficiency and editing specificity. Efficient C-to-T editing is achieved by BEACON in mammalian cells at levels comparable to AncBE4max, with only low levels of DDR and minimal RNA off-target mutations. Importantly, BEACON induces in vivo base editing in mouse embryos, and targeted C-to-T conversions are detected in F0 mice. Show less
no PDF DOI: 10.1016/j.celrep.2020.107723
HSD17B12
Yating Cheng, Yan Yang, Yinan Wu +7 more · 2020 · Frontiers in pharmacology · Frontiers · added 2026-04-24
The 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) enzyme is a potential therapeutic target for hormone-dependent prostate cancer, as it is the key enzyme in the last step of testosterone (T) bios Show more
The 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) enzyme is a potential therapeutic target for hormone-dependent prostate cancer, as it is the key enzyme in the last step of testosterone (T) biosynthesis. A curcumin analog, H10, was optimized for inhibiting T production in LC540 cells that stably overexpressed 17β-HSD3 enzyme (LC540 [17β-HSD3]) (P < 0.01), without affecting progesterone (P) synthesis. H10 downregulated the production of T in the microsomal fraction of rat testes containing the 17β-HSD3 enzyme from 100 to 78.41 ± 7.41%, 51.86 ± 10.03%, and 45.14 ± 8.49% at doses of 10, 20, and 40 μM, respectively. There were no significant differences among the groups with respect to the protein expression levels of 17β-HSD3, 3βHSD1, CYP17a1, CYP11a1, and STAR, which participate in 17β-HSD3-mediated conversion of androgens to T (P > 0.05). This indicated that H10 only inhibited the enzymatic activity of 17β-HSD3 Show less
📄 PDF DOI: 10.3389/fphar.2020.00637
HSD17B12
Man Zhang, Dan Li, Zhi-De Hu +1 more · 2020 · Annals of translational medicine · added 2026-04-24
Tuberculosis pleural effusion (TPE) is common in clinical practice, and its diagnosis remains a challenge for clinicians. Ziehl-Neelsen staining, PE Mycobacterium tuberculosis culture, and biopsy are Show more
Tuberculosis pleural effusion (TPE) is common in clinical practice, and its diagnosis remains a challenge for clinicians. Ziehl-Neelsen staining, PE Mycobacterium tuberculosis culture, and biopsy are the gold standards for TPE diagnosis; however, they are time-consuming, invasive, observer-dependent, and insensitive. PE markers represent a rapid, low-cost, and non-invasive objective diagnostic tool for TPE. In the past decades, several PE biomarkers have been developed, and their diagnostic accuracy has been evaluated in many studies. Here, we reviewed the literature to summarize the diagnostic accuracy of these biomarkers, especially using the evidence from systematic review and meta-analysis. The current research strongly suggests that adenosine deaminase (ADA), interferon-gamma (IFN-γ), and interleukin 27 (IL-27) have extremely higher diagnostic accuracy for TPE, while the diagnostic accuracy of interferon gamma release assays (IGRAs), tumor necrosis factor-α (TNF-α), and interferon-γ-induced protein 10 kDa (IP-10) is moderate. Although some evidence supports C-X-C motif chemokine ligand 9 (CXCL9), CXCL11, CXCL12, sFas ligand, angiotensin-converting enzyme (ACE), calpain-1, spectrin breakdown products (SBDP), matrix metalloproteinase-1 (MMP-1), soluble CD26 (sCD26), soluble interleukin 2 receptor (sIL-2R) as useful diagnostic markers for TPE, more support is needed to validate their diagnostic accuracy. Finally, nucleic acid amplification tests (NAATs) have extremely high diagnostic specificity, but their sensitivity is low. Taken together, ADA is the preferred marker for TPE because its low cost and suitability for standardization. Show less
📄 PDF DOI: 10.21037/atm.2019.09.110
IL27
Heng Zhang, Qingjie Li, Yuxin Teng +8 more · 2020 · Acta pharmaceutica Sinica. B · Elsevier · added 2026-04-24
Interleukin-27 (IL-27), a heterodimeric cytokine, plays a protective role in diabetes. Ghrelin, a gastric hormone, provides a hunger signal to the central nervous system to stimulate food intake. The Show more
Interleukin-27 (IL-27), a heterodimeric cytokine, plays a protective role in diabetes. Ghrelin, a gastric hormone, provides a hunger signal to the central nervous system to stimulate food intake. The relationship between IL-27 and ghrelin is still unexplored. Here we investigated that signal transducer and activator of transcription 3 (STAT3)-mechanistic target of rapamycin (mTOR) signaling mediates the suppression of ghrelin induced by IL-27. Co-localization of interleukin 27 receptor subunit alpha (WSX-1) and ghrelin was observed in mouse and human gastric mucosa. Intracerebroventricular injection of IL-27 markedly suppressed ghrelin synthesis and secretion while stimulating STAT3-mTOR signaling in both C57BL/6J mice and high-fat diet-induced-obese mice. IL-27 inhibited the production of ghrelin in mHypoE-N42 cells. Inhibition of mTOR activity induced by Show less
📄 PDF DOI: 10.1016/j.apsb.2019.12.018
IL27
Meng Zhang, Xiuxiu Tan, Junjie Huang +7 more · 2020 · Medical science monitor : international medical journal of experimental and clinical research · added 2026-04-24
The authors informed the journal that an error occurred in their manuscript.Figure 3C was mistakenly merged by the authors.The new version of the Figure 3C is as below.Reference:1. Meng Zhang, Xiuxiu Show more
The authors informed the journal that an error occurred in their manuscript.Figure 3C was mistakenly merged by the authors.The new version of the Figure 3C is as below.Reference:1. Meng Zhang, Xiuxiu Tan, Junjie Huang, Zekai Ke, Yukun Ge, Hu Xiong, Wei Lu, Lu Fang, Zhiming Cai, Song Wu: Association of 3 Common Polymorphisms of IL-27 Gene with Susceptibility to Cancer in Chinese: Evidence From an Updated Meta-Analysis of 27 Studies. Med Sci Monit 2015; 21: 2505-2513. DOI: 10.12659/MSM.895032. Show less
no PDF DOI: 10.12659/MSM.923878
IL27